International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment

Meletios A. Dimopoulos; Pieter Sonneveld; Nelson Leung; Giampaolo Merlini; Heinz Ludwig; Efstathios Kastritis; Hartmut Goldschmidt; Douglas Joshua; Robert Z. Orlowski; Raymond Powles; David H. Vesole; Laurent Garderet; Hermann Einsele; Antonio Palumbo; Michele Cavo; Paul G. Richardson; Philippe Moreau; Jesús San Miguel; S. Vincent Rajkumar; Brian G.M. Durie; Evangelos Terpos; Niels Abildgaard; Rafat Abonour; Melissa Alsina; Kenneth C. Anderson; Michel Attal; Hervé Avet-Loiseau; Ashraf Badros; Nizar Jacques Bahlis; Bart Barlogie; Régis Bataille; Meral Beksaç; Andrew Belch; Dina Ben-Yehuda; Bill Bensinger; P. Leif Bergsagel; Manisha Bhutani; Jenny Bird; Joan Bladé; Annemiek Broijl; Mario Boccadoro; Jo Caers; Asher Chanan-Khan; Ajai Chari; Wen Ming Chen; Marta Chesi; J. Anthony Child; Chor Sang Chim; Wee Joo Chng; Ray Comenzo; Gordon Cook; John Crowley; Edvan Crusoe; William Dalton; H. Lee Moffitt; Faith Davies; Javier de la Rubia; Cármino de Souza; Michel Delforge; Madhav Dhodapkar; Angela Dispenzieri; Johannes Drach; Matthew Drake; Juan Du; Dominik Dytfeld; Theirry Facon; Dorotea Fantl; Jean Paul Fermand; Carlos Fernández de Larrea; Rafael Fonseca; Gösta Gahrton; Ramón Garćia-Sanz; Christina Gasparetto; Morie Gertz; Irene Ghobrial; John Gibson; Peter Gimsing; Sergio Giralt; Jingli Gu; Roman Hajek; Izhar Hardan; Parameswaran Hari; Hiroyuki Hata; Yutaka Hattori; Tom Heffner; Jens Hillengass; Joy Ho; Antje Hoering; James Edward Hoffman; Jian Hou; Jeffrey Huang; Vania Hungria; Shinsuke Ida; Sundar Jagannath; Andrzej J. Jakubowiak; Hans Erik Johnsen; Artur Jurczyszyn; Martin Kaiser; Jonathan Kaufman; Michio Kawano; Neha Korde; Eva Kovacs; Amrita Krishnan; Sigurdur Kristinsson; Nicolaus Kröger; Shaji Kumar; Robert A. Kyle; Chara Kyriacou; Martha Lacy; Juan José Lahuerta; Ola Landgren; Alessandra Larocca; Jacob Laubach; Fernando Leal da Costa; Jae Hoon Lee; Merav Leiba; Xavier Leleu; Suzanne Lentzsch; Henk Lokhorst; Sagar Lonial; Jin Lu; Anuj Mahindra; Angelo Maiolino; Elisabet E. Manasanch; Tomer Mark; María Victoria Mateos; Amitabha Mazumder; Philip McCarthy; Jayesh Mehta; Ulf Henrik Mellqvist; Joseph Mikhael; Gareth Morgan; Nikhil Munshi; Hareth Nahi; Weerasak Nawarawong; Ruben Niesvizky; Amara Nouel; Yana Novis; Enrique Ocio; Michael O'Dwyer; Peter O'Gorman; Alberto Orfao; Paula Rodriguez Otero; Bruno Paiva; Santiago Pavlovsky; Linda Pilarski; Guy Pratt; Lugui Qui; Noopur Raje; Donna Reece; Anthony Reiman; Guillermina Remaggi; Joshua Richter; Eloísa Riva Serra; Angelina Rodríguez Morales; Kenneth R. Romeril; David Roodman; Laura Rosiñol; Adriana Rossi; Murielle Roussel; Stephen Russell; Fredrik Schjesvold; Rik Schots; Sabina Sevcikova; Orhan Sezer; Jatin J. Shah; Kazuyuki Shimizu; Chaim Shustik; David Siegel; Seema Singhal; Andrew Spencer; Edward Stadtmauer; Keith Stewart; Daryl Tan; Carolina Terragna; Patrizia Tosi; Guido Tricot; Ingemar Turesson; Saad Usmani; Ben Van Camp; Niels Van de Donk; Brian Van Ness; Ivan Van Riet; Isabelle Vande Broek; Karin Vanderkerken; Robert Vescio; Ravi Vij; Peter Voorhees; Anders Waage; Michael Wang; Donna Weber; Brendan M. Weiss; Jan Westin; Keith Wheatley; Elena Zamagni; Jeffrey Zonder; Sonja Zweegman

doi:10.1200/JCO.2015.65.0044

International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment

Meletios A. Dimopoulos, Pieter Sonneveld, Nelson Leung, Giampaolo Merlini, Heinz Ludwig, Efstathios Kastritis, Hartmut Goldschmidt, Douglas Joshua, Robert Z. Orlowski, Raymond Powles, David H. Vesole, Laurent Garderet, Hermann Einsele, Antonio Palumbo, Michele Cavo, Paul G. Richardson, Philippe Moreau, Jesús San Miguel, S. Vincent Rajkumar, Brian G.M. DurieEvangelos Terpos, Niels Abildgaard, Rafat Abonour, Melissa Alsina, Kenneth C. Anderson, Michel Attal, Hervé Avet-Loiseau, Ashraf Badros, Nizar Jacques Bahlis, Bart Barlogie, Régis Bataille, Meral Beksaç, Andrew Belch, Dina Ben-Yehuda, Bill Bensinger, P. Leif Bergsagel, Manisha Bhutani, Jenny Bird, Joan Bladé, Annemiek Broijl, Mario Boccadoro, Jo Caers, Asher Chanan-Khan, Ajai Chari, Wen Ming Chen, Marta Chesi, J. Anthony Child, Chor Sang Chim, Wee Joo Chng, Ray Comenzo, Gordon Cook, John Crowley, Edvan Crusoe, William Dalton, H. Lee Moffitt, Faith Davies, Javier de la Rubia, Cármino de Souza, Michel Delforge, Madhav Dhodapkar, Angela Dispenzieri, Johannes Drach, Matthew Drake, Juan Du, Dominik Dytfeld, Theirry Facon, Dorotea Fantl, Jean Paul Fermand, Carlos Fernández de Larrea, Rafael Fonseca, Gösta Gahrton, Ramón Garćia-Sanz, Christina Gasparetto, Morie Gertz, Irene Ghobrial, John Gibson, Peter Gimsing, Sergio Giralt, Jingli Gu, Roman Hajek, Izhar Hardan, Parameswaran Hari, Hiroyuki Hata, Yutaka Hattori, Tom Heffner, Jens Hillengass, Joy Ho, Antje Hoering, James Edward Hoffman, Jian Hou, Jeffrey Huang, Vania Hungria, Shinsuke Ida, Sundar Jagannath, Andrzej J. Jakubowiak, Hans Erik Johnsen, Artur Jurczyszyn, Martin Kaiser, Jonathan Kaufman, Michio Kawano, Neha Korde, Eva Kovacs, Amrita Krishnan, Sigurdur Kristinsson, Nicolaus Kröger, Shaji Kumar, Robert A. Kyle, Chara Kyriacou, Martha Lacy, Juan José Lahuerta, Ola Landgren, Alessandra Larocca, Jacob Laubach, Fernando Leal da Costa, Jae Hoon Lee, Merav Leiba, Xavier Leleu, Suzanne Lentzsch, Henk Lokhorst, Sagar Lonial, Jin Lu, Anuj Mahindra, Angelo Maiolino, Elisabet E. Manasanch, Tomer Mark, María Victoria Mateos, Amitabha Mazumder, Philip McCarthy, Jayesh Mehta, Ulf Henrik Mellqvist, Joseph Mikhael, Gareth Morgan, Nikhil Munshi, Hareth Nahi, Weerasak Nawarawong, Ruben Niesvizky, Amara Nouel, Yana Novis, Enrique Ocio, Michael O'Dwyer, Peter O'Gorman, Alberto Orfao, Paula Rodriguez Otero, Bruno Paiva, Santiago Pavlovsky, Linda Pilarski, Guy Pratt, Lugui Qui, Noopur Raje, Donna Reece, Anthony Reiman, Guillermina Remaggi, Joshua Richter, Eloísa Riva Serra, Angelina Rodríguez Morales, Kenneth R. Romeril, David Roodman, Laura Rosiñol, Adriana Rossi, Murielle Roussel, Stephen Russell, Fredrik Schjesvold, Rik Schots, Sabina Sevcikova, Orhan Sezer, Jatin J. Shah, Kazuyuki Shimizu, Chaim Shustik, David Siegel, Seema Singhal, Andrew Spencer, Edward Stadtmauer, Keith Stewart, Daryl Tan, Carolina Terragna, Patrizia Tosi, Guido Tricot, Ingemar Turesson, Saad Usmani, Ben Van Camp, Niels Van de Donk, Brian Van Ness, Ivan Van Riet, Isabelle Vande Broek, Karin Vanderkerken, Robert Vescio, Ravi Vij, Peter Voorhees, Anders Waage, Michael Wang, Donna Weber, Brendan M. Weiss, Jan Westin, Keith Wheatley, Elena Zamagni, Jeffrey Zonder, Sonja Zweegman

Genetics, Cell Biology and Development (TMED)

Research output: Contribution to journal › Article › peer-review

283 Scopus citations

Abstract

Purpose: The aim of the International Myeloma Working Group was to develop practical recommendations for the diagnosis and management of multiple myeloma–related renal impairment (RI). Methods: Recommendations were based on published data through December 2015, and were developed using the system developed by the Grading of Recommendation, Assessment, Development, and Evaluation Working Group. Recommendations: All patients with myeloma at diagnosis and at disease assessment should have serum creatinine, estimated glomerular filtration rate, and electrolytes measurements as well as free light chain, if available, and urine electrophoresis of a sample from a 24-hour urine collection (grade A). The Chronic Kidney Disease Epidemiology Collaboration, preferably, or the Modification of Diet in Renal Disease formula should be used for the evaluation of estimated glomerular filtration rate in patients with stabilized serum creatinine (grade A). International Myeloma Working Group criteria for renal reversibility should be used (grade B). For the management of RI in patients with multiple myeloma, high fluid intake is indicated along with antimyeloma therapy (grade B). The use of high-cutoff hemodialysis membranes in combination with antimyeloma therapy can be considered (grade B). Bortezomib-based regimens remain the cornerstone of the management of myeloma-related RI (grade A). High-dose dexamethasone should be administered at least for the first month of therapy (grade B). Thalidomide is effective in patients with myeloma with RI, and no dose modifications are needed (grade B). Lenalidomide is effective and safe, mainly in patients with mild to moderate RI (grade B); for patients with severe RI or on dialysis, lena-lidomide should be given with close monitoring for hematologic toxicity (grade B) with dose reduction as needed. High-dose therapy with autologous stem cell transplantation (with melphalan 100 mg/m² to 140 mg/m²) is feasible in patients with RI (grade C). Carfilzomib can be safely administered to patients with creatinine clearance > 15 mL/min, whereas ixazomib in combination with lenalidomide and dex-amethasone can be safely administered to patients with creatinine clearance > 30 mL/min (grade A).

Original language	English (US)
Pages (from-to)	1544-1557
Number of pages	14
Journal	Journal of Clinical Oncology
Volume	34
Issue number	13
DOIs	https://doi.org/10.1200/JCO.2015.65.0044
State	Published - May 1 2016

Bibliographical note

Publisher Copyright:
© 2016 by American Society of Clinical Oncology.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1200/JCO.2015.65.0044

OpenUrl availability

Full text

Cite this

Dimopoulos, M. A., Sonneveld, P., Leung, N., Merlini, G., Ludwig, H., Kastritis, E., Goldschmidt, H., Joshua, D., Orlowski, R. Z., Powles, R., Vesole, D. H., Garderet, L., Einsele, H., Palumbo, A., Cavo, M., Richardson, P. G., Moreau, P., Miguel, J. S., Vincent Rajkumar, S., ... Zweegman, S. (2016). International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment. Journal of Clinical Oncology, 34(13), 1544-1557. https://doi.org/10.1200/JCO.2015.65.0044

Dimopoulos, MA, Sonneveld, P, Leung, N, Merlini, G, Ludwig, H, Kastritis, E, Goldschmidt, H, Joshua, D, Orlowski, RZ, Powles, R, Vesole, DH, Garderet, L, Einsele, H, Palumbo, A, Cavo, M, Richardson, PG, Moreau, P, Miguel, JS, Vincent Rajkumar, S, Durie, BGM, Terpos, E, Abildgaard, N, Abonour, R, Alsina, M, Anderson, KC, Attal, M, Avet-Loiseau, H, Badros, A, Bahlis, NJ, Barlogie, B, Bataille, R, Beksaç, M, Belch, A, Ben-Yehuda, D, Bensinger, B, Leif Bergsagel, P, Bhutani, M, Bird, J, Bladé, J, Broijl, A, Boccadoro, M, Caers, J, Chanan-Khan, A, Chari, A, Chen, WM, Chesi, M, Anthony Child, J, Chim, CS, Chng, WJ, Comenzo, R, Cook, G, Crowley, J, Crusoe, E, Dalton, W, Lee Moffitt, H, Davies, F, de la Rubia, J, de Souza, C, Delforge, M, Dhodapkar, M, Dispenzieri, A, Drach, J, Drake, M, Du, J, Dytfeld, D, Facon, T, Fantl, D, Fermand, JP, Fernández de Larrea, C, Fonseca, R, Gahrton, G, Garćia-Sanz, R, Gasparetto, C, Gertz, M, Ghobrial, I, Gibson, J, Gimsing, P, Giralt, S, Gu, J, Hajek, R, Hardan, I, Hari, P, Hata, H, Hattori, Y, Heffner, T, Hillengass, J, Ho, J, Hoering, A, Hoffman, JE, Hou, J, Huang, J, Hungria, V, Ida, S, Jagannath, S, Jakubowiak, AJ, Johnsen, HE, Jurczyszyn, A, Kaiser, M, Kaufman, J, Kawano, M, Korde, N, Kovacs, E, Krishnan, A, Kristinsson, S, Kröger, N, Kumar, S, Kyle, RA, Kyriacou, C, Lacy, M, Lahuerta, JJ, Landgren, O, Larocca, A, Laubach, J, da Costa, FL, Lee, JH, Leiba, M, Leleu, X, Lentzsch, S, Lokhorst, H, Lonial, S, Lu, J, Mahindra, A, Maiolino, A, Manasanch, EE, Mark, T, Mateos, MV, Mazumder, A, McCarthy, P, Mehta, J, Mellqvist, UH, Mikhael, J, Morgan, G, Munshi, N, Nahi, H, Nawarawong, W, Niesvizky, R, Nouel, A, Novis, Y, Ocio, E, O'Dwyer, M, O'Gorman, P, Orfao, A, Otero, PR, Paiva, B, Pavlovsky, S, Pilarski, L, Pratt, G, Qui, L, Raje, N, Reece, D, Reiman, A, Remaggi, G, Richter, J, Serra, ER, Morales, AR, Romeril, KR, Roodman, D, Rosiñol, L, Rossi, A, Roussel, M, Russell, S, Schjesvold, F, Schots, R, Sevcikova, S, Sezer, O, Shah, JJ, Shimizu, K, Shustik, C, Siegel, D, Singhal, S, Spencer, A, Stadtmauer, E, Stewart, K, Tan, D, Terragna, C, Tosi, P, Tricot, G, Turesson, I, Usmani, S, Van Camp, B, Van de Donk, N, Van Ness, B, Van Riet, I, Broek, IV, Vanderkerken, K, Vescio, R, Vij, R, Voorhees, P, Waage, A, Wang, M, Weber, D, Weiss, BM, Westin, J, Wheatley, K, Zamagni, E, Zonder, J & Zweegman, S 2016, 'International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment', Journal of Clinical Oncology, vol. 34, no. 13, pp. 1544-1557. https://doi.org/10.1200/JCO.2015.65.0044

@article{6db18414aa824f71bcbdd2b622dedff1,

title = "International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment",

abstract = "Purpose: The aim of the International Myeloma Working Group was to develop practical recommendations for the diagnosis and management of multiple myeloma–related renal impairment (RI). Methods: Recommendations were based on published data through December 2015, and were developed using the system developed by the Grading of Recommendation, Assessment, Development, and Evaluation Working Group. Recommendations: All patients with myeloma at diagnosis and at disease assessment should have serum creatinine, estimated glomerular filtration rate, and electrolytes measurements as well as free light chain, if available, and urine electrophoresis of a sample from a 24-hour urine collection (grade A). The Chronic Kidney Disease Epidemiology Collaboration, preferably, or the Modification of Diet in Renal Disease formula should be used for the evaluation of estimated glomerular filtration rate in patients with stabilized serum creatinine (grade A). International Myeloma Working Group criteria for renal reversibility should be used (grade B). For the management of RI in patients with multiple myeloma, high fluid intake is indicated along with antimyeloma therapy (grade B). The use of high-cutoff hemodialysis membranes in combination with antimyeloma therapy can be considered (grade B). Bortezomib-based regimens remain the cornerstone of the management of myeloma-related RI (grade A). High-dose dexamethasone should be administered at least for the first month of therapy (grade B). Thalidomide is effective in patients with myeloma with RI, and no dose modifications are needed (grade B). Lenalidomide is effective and safe, mainly in patients with mild to moderate RI (grade B); for patients with severe RI or on dialysis, lena-lidomide should be given with close monitoring for hematologic toxicity (grade B) with dose reduction as needed. High-dose therapy with autologous stem cell transplantation (with melphalan 100 mg/m2 to 140 mg/m2) is feasible in patients with RI (grade C). Carfilzomib can be safely administered to patients with creatinine clearance > 15 mL/min, whereas ixazomib in combination with lenalidomide and dex-amethasone can be safely administered to patients with creatinine clearance > 30 mL/min (grade A).",

author = "Dimopoulos, {Meletios A.} and Pieter Sonneveld and Nelson Leung and Giampaolo Merlini and Heinz Ludwig and Efstathios Kastritis and Hartmut Goldschmidt and Douglas Joshua and Orlowski, {Robert Z.} and Raymond Powles and Vesole, {David H.} and Laurent Garderet and Hermann Einsele and Antonio Palumbo and Michele Cavo and Richardson, {Paul G.} and Philippe Moreau and Miguel, {Jes{\'u}s San} and {Vincent Rajkumar}, S. and Durie, {Brian G.M.} and Evangelos Terpos and Niels Abildgaard and Rafat Abonour and Melissa Alsina and Anderson, {Kenneth C.} and Michel Attal and Herv{\'e} Avet-Loiseau and Ashraf Badros and Bahlis, {Nizar Jacques} and Bart Barlogie and R{\'e}gis Bataille and Meral Beksa{\c c} and Andrew Belch and Dina Ben-Yehuda and Bill Bensinger and {Leif Bergsagel}, P. and Manisha Bhutani and Jenny Bird and Joan Blad{\'e} and Annemiek Broijl and Mario Boccadoro and Jo Caers and Asher Chanan-Khan and Ajai Chari and Chen, {Wen Ming} and Marta Chesi and {Anthony Child}, J. and Chim, {Chor Sang} and Chng, {Wee Joo} and Ray Comenzo and Gordon Cook and John Crowley and Edvan Crusoe and William Dalton and {Lee Moffitt}, H. and Faith Davies and {de la Rubia}, Javier and {de Souza}, C{\'a}rmino and Michel Delforge and Madhav Dhodapkar and Angela Dispenzieri and Johannes Drach and Matthew Drake and Juan Du and Dominik Dytfeld and Theirry Facon and Dorotea Fantl and Fermand, {Jean Paul} and {Fern{\'a}ndez de Larrea}, Carlos and Rafael Fonseca and G{\"o}sta Gahrton and Ram{\'o}n Gar{\'c}ia-Sanz and Christina Gasparetto and Morie Gertz and Irene Ghobrial and John Gibson and Peter Gimsing and Sergio Giralt and Jingli Gu and Roman Hajek and Izhar Hardan and Parameswaran Hari and Hiroyuki Hata and Yutaka Hattori and Tom Heffner and Jens Hillengass and Joy Ho and Antje Hoering and Hoffman, {James Edward} and Jian Hou and Jeffrey Huang and Vania Hungria and Shinsuke Ida and Sundar Jagannath and Jakubowiak, {Andrzej J.} and Johnsen, {Hans Erik} and Artur Jurczyszyn and Martin Kaiser and Jonathan Kaufman and Michio Kawano and Neha Korde and Eva Kovacs and Amrita Krishnan and Sigurdur Kristinsson and Nicolaus Kr{\"o}ger and Shaji Kumar and Kyle, {Robert A.} and Chara Kyriacou and Martha Lacy and Lahuerta, {Juan Jos{\'e}} and Ola Landgren and Alessandra Larocca and Jacob Laubach and {da Costa}, {Fernando Leal} and Lee, {Jae Hoon} and Merav Leiba and Xavier Leleu and Suzanne Lentzsch and Henk Lokhorst and Sagar Lonial and Jin Lu and Anuj Mahindra and Angelo Maiolino and Manasanch, {Elisabet E.} and Tomer Mark and Mateos, {Mar{\'i}a Victoria} and Amitabha Mazumder and Philip McCarthy and Jayesh Mehta and Mellqvist, {Ulf Henrik} and Joseph Mikhael and Gareth Morgan and Nikhil Munshi and Hareth Nahi and Weerasak Nawarawong and Ruben Niesvizky and Amara Nouel and Yana Novis and Enrique Ocio and Michael O'Dwyer and Peter O'Gorman and Alberto Orfao and Otero, {Paula Rodriguez} and Bruno Paiva and Santiago Pavlovsky and Linda Pilarski and Guy Pratt and Lugui Qui and Noopur Raje and Donna Reece and Anthony Reiman and Guillermina Remaggi and Joshua Richter and Serra, {Elo{\'i}sa Riva} and Morales, {Angelina Rodr{\'i}guez} and Romeril, {Kenneth R.} and David Roodman and Laura Rosi{\~n}ol and Adriana Rossi and Murielle Roussel and Stephen Russell and Fredrik Schjesvold and Rik Schots and Sabina Sevcikova and Orhan Sezer and Shah, {Jatin J.} and Kazuyuki Shimizu and Chaim Shustik and David Siegel and Seema Singhal and Andrew Spencer and Edward Stadtmauer and Keith Stewart and Daryl Tan and Carolina Terragna and Patrizia Tosi and Guido Tricot and Ingemar Turesson and Saad Usmani and {Van Camp}, Ben and {Van de Donk}, Niels and {Van Ness}, Brian and {Van Riet}, Ivan and Broek, {Isabelle Vande} and Karin Vanderkerken and Robert Vescio and Ravi Vij and Peter Voorhees and Anders Waage and Michael Wang and Donna Weber and Weiss, {Brendan M.} and Jan Westin and Keith Wheatley and Elena Zamagni and Jeffrey Zonder and Sonja Zweegman",

note = "Publisher Copyright: {\textcopyright} 2016 by American Society of Clinical Oncology.",

year = "2016",

month = may,

day = "1",

doi = "10.1200/JCO.2015.65.0044",

language = "English (US)",

volume = "34",

pages = "1544--1557",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "13",

}

TY - JOUR

T1 - International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment

AU - Dimopoulos, Meletios A.

AU - Sonneveld, Pieter

AU - Leung, Nelson

AU - Merlini, Giampaolo

AU - Ludwig, Heinz

AU - Kastritis, Efstathios

AU - Goldschmidt, Hartmut

AU - Joshua, Douglas

AU - Orlowski, Robert Z.

AU - Powles, Raymond

AU - Vesole, David H.

AU - Garderet, Laurent

AU - Einsele, Hermann

AU - Palumbo, Antonio

AU - Cavo, Michele

AU - Richardson, Paul G.

AU - Moreau, Philippe

AU - Miguel, Jesús San

AU - Vincent Rajkumar, S.

AU - Durie, Brian G.M.

AU - Terpos, Evangelos

AU - Abildgaard, Niels

AU - Abonour, Rafat

AU - Alsina, Melissa

AU - Anderson, Kenneth C.

AU - Attal, Michel

AU - Avet-Loiseau, Hervé

AU - Badros, Ashraf

AU - Bahlis, Nizar Jacques

AU - Barlogie, Bart

AU - Bataille, Régis

AU - Beksaç, Meral

AU - Belch, Andrew

AU - Ben-Yehuda, Dina

AU - Bensinger, Bill

AU - Leif Bergsagel, P.

AU - Bhutani, Manisha

AU - Bird, Jenny

AU - Bladé, Joan

AU - Broijl, Annemiek

AU - Boccadoro, Mario

AU - Caers, Jo

AU - Chanan-Khan, Asher

AU - Chari, Ajai

AU - Chen, Wen Ming

AU - Chesi, Marta

AU - Anthony Child, J.

AU - Chim, Chor Sang

AU - Chng, Wee Joo

AU - Comenzo, Ray

AU - Cook, Gordon

AU - Crowley, John

AU - Crusoe, Edvan

AU - Dalton, William

AU - Lee Moffitt, H.

AU - Davies, Faith

AU - de la Rubia, Javier

AU - de Souza, Cármino

AU - Delforge, Michel

AU - Dhodapkar, Madhav

AU - Dispenzieri, Angela

AU - Drach, Johannes

AU - Drake, Matthew

AU - Du, Juan

AU - Dytfeld, Dominik

AU - Facon, Theirry

AU - Fantl, Dorotea

AU - Fermand, Jean Paul

AU - Fernández de Larrea, Carlos

AU - Fonseca, Rafael

AU - Gahrton, Gösta

AU - Garćia-Sanz, Ramón

AU - Gasparetto, Christina

AU - Gertz, Morie

AU - Ghobrial, Irene

AU - Gibson, John

AU - Gimsing, Peter

AU - Giralt, Sergio

AU - Gu, Jingli

AU - Hajek, Roman

AU - Hardan, Izhar

AU - Hari, Parameswaran

AU - Hata, Hiroyuki

AU - Hattori, Yutaka

AU - Heffner, Tom

AU - Hillengass, Jens

AU - Ho, Joy

AU - Hoering, Antje

AU - Hoffman, James Edward

AU - Hou, Jian

AU - Huang, Jeffrey

AU - Hungria, Vania

AU - Ida, Shinsuke

AU - Jagannath, Sundar

AU - Jakubowiak, Andrzej J.

AU - Johnsen, Hans Erik

AU - Jurczyszyn, Artur

AU - Kaiser, Martin

AU - Kaufman, Jonathan

AU - Kawano, Michio

AU - Korde, Neha

AU - Kovacs, Eva

AU - Krishnan, Amrita

AU - Kristinsson, Sigurdur

AU - Kröger, Nicolaus

AU - Kumar, Shaji

AU - Kyle, Robert A.

AU - Kyriacou, Chara

AU - Lacy, Martha

AU - Lahuerta, Juan José

AU - Landgren, Ola

AU - Larocca, Alessandra

AU - Laubach, Jacob

AU - da Costa, Fernando Leal

AU - Lee, Jae Hoon

AU - Leiba, Merav

AU - Leleu, Xavier

AU - Lentzsch, Suzanne

AU - Lokhorst, Henk

AU - Lonial, Sagar

AU - Lu, Jin

AU - Mahindra, Anuj

AU - Maiolino, Angelo

AU - Manasanch, Elisabet E.

AU - Mark, Tomer

AU - Mateos, María Victoria

AU - Mazumder, Amitabha

AU - McCarthy, Philip

AU - Mehta, Jayesh

AU - Mellqvist, Ulf Henrik

AU - Mikhael, Joseph

AU - Morgan, Gareth

AU - Munshi, Nikhil

AU - Nahi, Hareth

AU - Nawarawong, Weerasak

AU - Niesvizky, Ruben

AU - Nouel, Amara

AU - Novis, Yana

AU - Ocio, Enrique

AU - O'Dwyer, Michael

AU - O'Gorman, Peter

AU - Orfao, Alberto

AU - Otero, Paula Rodriguez

AU - Paiva, Bruno

AU - Pavlovsky, Santiago

AU - Pilarski, Linda

AU - Pratt, Guy

AU - Qui, Lugui

AU - Raje, Noopur

AU - Reece, Donna

AU - Reiman, Anthony

AU - Remaggi, Guillermina

AU - Richter, Joshua

AU - Serra, Eloísa Riva

AU - Morales, Angelina Rodríguez

AU - Romeril, Kenneth R.

AU - Roodman, David

AU - Rosiñol, Laura

AU - Rossi, Adriana

AU - Roussel, Murielle

AU - Russell, Stephen

AU - Schjesvold, Fredrik

AU - Schots, Rik

AU - Sevcikova, Sabina

AU - Sezer, Orhan

AU - Shah, Jatin J.

AU - Shimizu, Kazuyuki

AU - Shustik, Chaim

AU - Siegel, David

AU - Singhal, Seema

AU - Spencer, Andrew

AU - Stadtmauer, Edward

AU - Stewart, Keith

AU - Tan, Daryl

AU - Terragna, Carolina

AU - Tosi, Patrizia

AU - Tricot, Guido

AU - Turesson, Ingemar

AU - Usmani, Saad

AU - Van Camp, Ben

AU - Van de Donk, Niels

AU - Van Ness, Brian

AU - Van Riet, Ivan

AU - Broek, Isabelle Vande

AU - Vanderkerken, Karin

AU - Vescio, Robert

AU - Vij, Ravi

AU - Voorhees, Peter

AU - Waage, Anders

AU - Wang, Michael

AU - Weber, Donna

AU - Weiss, Brendan M.

AU - Westin, Jan

AU - Wheatley, Keith

AU - Zamagni, Elena

AU - Zonder, Jeffrey

AU - Zweegman, Sonja

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Purpose: The aim of the International Myeloma Working Group was to develop practical recommendations for the diagnosis and management of multiple myeloma–related renal impairment (RI). Methods: Recommendations were based on published data through December 2015, and were developed using the system developed by the Grading of Recommendation, Assessment, Development, and Evaluation Working Group. Recommendations: All patients with myeloma at diagnosis and at disease assessment should have serum creatinine, estimated glomerular filtration rate, and electrolytes measurements as well as free light chain, if available, and urine electrophoresis of a sample from a 24-hour urine collection (grade A). The Chronic Kidney Disease Epidemiology Collaboration, preferably, or the Modification of Diet in Renal Disease formula should be used for the evaluation of estimated glomerular filtration rate in patients with stabilized serum creatinine (grade A). International Myeloma Working Group criteria for renal reversibility should be used (grade B). For the management of RI in patients with multiple myeloma, high fluid intake is indicated along with antimyeloma therapy (grade B). The use of high-cutoff hemodialysis membranes in combination with antimyeloma therapy can be considered (grade B). Bortezomib-based regimens remain the cornerstone of the management of myeloma-related RI (grade A). High-dose dexamethasone should be administered at least for the first month of therapy (grade B). Thalidomide is effective in patients with myeloma with RI, and no dose modifications are needed (grade B). Lenalidomide is effective and safe, mainly in patients with mild to moderate RI (grade B); for patients with severe RI or on dialysis, lena-lidomide should be given with close monitoring for hematologic toxicity (grade B) with dose reduction as needed. High-dose therapy with autologous stem cell transplantation (with melphalan 100 mg/m2 to 140 mg/m2) is feasible in patients with RI (grade C). Carfilzomib can be safely administered to patients with creatinine clearance > 15 mL/min, whereas ixazomib in combination with lenalidomide and dex-amethasone can be safely administered to patients with creatinine clearance > 30 mL/min (grade A).

AB - Purpose: The aim of the International Myeloma Working Group was to develop practical recommendations for the diagnosis and management of multiple myeloma–related renal impairment (RI). Methods: Recommendations were based on published data through December 2015, and were developed using the system developed by the Grading of Recommendation, Assessment, Development, and Evaluation Working Group. Recommendations: All patients with myeloma at diagnosis and at disease assessment should have serum creatinine, estimated glomerular filtration rate, and electrolytes measurements as well as free light chain, if available, and urine electrophoresis of a sample from a 24-hour urine collection (grade A). The Chronic Kidney Disease Epidemiology Collaboration, preferably, or the Modification of Diet in Renal Disease formula should be used for the evaluation of estimated glomerular filtration rate in patients with stabilized serum creatinine (grade A). International Myeloma Working Group criteria for renal reversibility should be used (grade B). For the management of RI in patients with multiple myeloma, high fluid intake is indicated along with antimyeloma therapy (grade B). The use of high-cutoff hemodialysis membranes in combination with antimyeloma therapy can be considered (grade B). Bortezomib-based regimens remain the cornerstone of the management of myeloma-related RI (grade A). High-dose dexamethasone should be administered at least for the first month of therapy (grade B). Thalidomide is effective in patients with myeloma with RI, and no dose modifications are needed (grade B). Lenalidomide is effective and safe, mainly in patients with mild to moderate RI (grade B); for patients with severe RI or on dialysis, lena-lidomide should be given with close monitoring for hematologic toxicity (grade B) with dose reduction as needed. High-dose therapy with autologous stem cell transplantation (with melphalan 100 mg/m2 to 140 mg/m2) is feasible in patients with RI (grade C). Carfilzomib can be safely administered to patients with creatinine clearance > 15 mL/min, whereas ixazomib in combination with lenalidomide and dex-amethasone can be safely administered to patients with creatinine clearance > 30 mL/min (grade A).

UR - http://www.scopus.com/inward/record.url?scp=84965050407&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84965050407&partnerID=8YFLogxK

U2 - 10.1200/JCO.2015.65.0044

DO - 10.1200/JCO.2015.65.0044

M3 - Article

C2 - 26976420

AN - SCOPUS:84965050407

SN - 0732-183X

VL - 34

SP - 1544

EP - 1557

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 13

ER -

International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment

Abstract

Bibliographical note

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this